COMBINATION THERAPY WITH FAP-TARGETED CD40 AGONISTS

The present invention relates to combination therapies employing FAP-targeted CD40 agonists, in particular bispecific antigen binding molecules comprising at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) and at least one antigen binding domain ca...

Full description

Saved in:
Bibliographic Details
Main Authors LABIANO ALMINANA, Sara, UMAÑA, Pablo, VOZENIN, Marie, Catherine, TOLSTONOG, Genrich, TRUMPELLER, Christine, ROMERO, Pedro
Format Patent
LanguageEnglish
French
German
Published 20.09.2023
Subjects
CHEMISTRY
ELECTROTHERAPY
HUMAN NECESSITIES
HYGIENE
MAGNETOTHERAPY
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
RADIATION THERAPY
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
ULTRASOUND THERAPY
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to combination therapies employing FAP-targeted CD40 agonists, in particular bispecific antigen binding molecules comprising at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) and at least one antigen binding domain capable of specific binding to CD40, and radiotherapy.
Bibliography:Application Number: EP20210810019